amgen challeng alexion soliri patent sell-off
unwarr ultomiri potenti
page full analyst note aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim
price data sep
rate updat sep
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
alexion pharmaceut land uniqu ultra-rare-diseas
blockbust soliri expand reach
origin approv paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom ahu gener
myasthenia gravi gmg neuromyel optica
spectrum disord nmosd approv alexion provid
disease-modifi treatment avail
indic give firm substanti price power patient
share potenti expand new indic two
drug ultra-rar diseas strensiq kanuma promis
pipelin special salesforc believ alexion
well-posit retain lead statu rare-diseas market
despit outsiz success soliri alexion come
turbul year expens acquisit metabol
indic investig aggress sell tactic
nearli complet manag turnov restructur
program believ alexion final side
seriou misstep execut previou manag
new leadership record larg unprov strong
launch gmg approv ultomiri recent promis
early-stag acquisit point new era beleagu
pipelin competit grow drug manufactur flock
lucr autoimmun market alexion first-mov statu
well ultomiri relat pipelin mitig risk
addit firm continu drive growth
identif new patient across globe alexion
special salesforc strong entrench patient
doctor rais barrier entri brand competitor
soliri high price draw question price pressur whether
polit motiv incit mount competit
howev volum growth label expans conveni
dose ultomiri alreadi cheaper soliri
help stave consider price headwind biosimilar
brand competitor encroach indic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria atyp hemolyt
urem syndrom gener myasthenia gravi next-gener
ultomiri recent approv paroxysm nocturn hemoglobinuria
strensiq kanuma target ultrarar metabol diseas alexion
rare diseas high unmet need
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
amgen challeng alexion soliri patent sell-
unwarr ultomiri potenti aug
narrow-moat alexion receiv disappoint news aug
 patent trial appeal board announc
would institut inter part review ipr evalu
valid three soliri patent issu
would extend patent protect soliri
approv four rare diseas contribut
billion revenu challeng came rival
develop soliri biosimilar could
launch depend valid alexion
patent outcom clinic trial news
ipr took market analyst surpris send
share friday morn believ sell-
unwarr long-term thesi rest alexion
convert patient soliri ultomiri
arsen patent protect maintain
fair valu estim per share continu view
share under-valued howev would surpris
see protract overhang stock given ipr
could last late
analysi assum biosimilar competit paroxysm
nocturn hemoglobinuria
intern think switch patient ultomiri
stymi biosimilar share gain given conveni
dose infus everi two month instead soliri everi
two week slightli lower price notabl alexion
alreadi success switch patient
ultomiri pnh patient switch juli
give us confid project
narrow-moat rate alexion subcutan
version ultomiri success clinic trial
anticip conveni ultomiri inject
incentiv patient doctor treat
depend clinic outcom
news ipr come roughli week rumor
spanish news sourc would acquir
alexion lift share aug
view takeout rumor low credibl given
develop soliri biosimilar
rumor larg dispel follow week news
purchas otezla celgen
key driver per share fair valu estim
price volum alexion key drug soliri
ultomiri model steadi revenu growth
driven modest patient growth pnh ahu
dampen slightli push convert patient
ultomiri solid growth gmg approv
success roll-out nmosd approv
model single-digit price headwind soliri
ultomiri probability-weight competitor entri start
biosimilar entri throughout explicit forecast
project assum substanti patient declin pnh
ahu due biosimilar slightli larger hit
outsid howev regulatori orphan drug
exclus newer launch gmg nmosd
also larger address patient popul bolster
alexion posit price headwind off-set volum
increas led gmg nmosd
pipelin contribut million
probability-adjust sale given
candid earli stage posit trial readout
pipelin could provid upsid valuat
strensiq kanuma grow modestli throughout
forecast believ face competitor
given obscur indic result five-year
revenu compound-annual-growth-rate low-single-digit revenu
compound-annual-growth-rate despit continu increas
oper expens fund commerci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
price headwind compani see essenti flat
revenu case fair valu
estim per share
ultrarar rare diseas high unmet medic need
ultrarar paroxysm nocturn hemoglobinuria pnh
alexion blockbust drug soliri extend
reach ultrarar atyp hemolyt urem syndrom
ahu rare gener myasthenia gravi
gmg approv rare
neuromyel optica spectrum disord nmosd
soliri patent protect market exclus pnh
ahu set expir next five year orphan drug
exclus continu provid protect gmg
nmosd larger target popul still fit
compani focu rare life-threaten
diseas avail treatment option furthermor
next-gener ultomiri approv pnh end
offer conveni dose schedul
opportun maintain signific market share
addit patent protect market exclus strensiq
ultrarar hypophosphatasia kanuma
ultrarar lysosom acid lipas defici lal-d
launch pair alexion pipelin
candid rare indic provid diversif
alexion
treatment option
patient autoimmun metabol diseas
target compani drug pipelin
prognos caus diseas slightli differ
patient pnh ahu devast
uncontrol activ immun system specif
part call complement result chronic
destruct red blood cell lead blood clot
organ failur thirty-f percent pnh patient die within
revenu growth
end forecast
compani long-term outcom hing factor
includ success convert patient soliri
ultomiri time subcutan version ultomiri
time competitor entri result believ
alexion face rather wide rang possibl outcom
give compani high uncertainti rate
bear case brand competitor biosimilar
larger impact alexion sale competitor
captur outsiz patient share base price safeti
efficaci case alexion face annual
double-digit price headwind ultomiri pipelin
failur result substanti revenu declin
fair valu estim per
bull case brand competitor fail reach approv
impact biosimilar mute thank ultomiri
attract dose schedul price model smaller
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
five year ahu patient progress end-stag
renal diseas lal-d patient miss key
enzym critic metabol function case
onset diseas start birth close
birth patient die organ failur within year gmg
nmosd character unpredict relaps
includ life-threaten symptom like respiratori
failur gmg nmosd well blind
paralysi nmosd access alexion drug
matter life death alexion treat
exclud gmg launch one year ago
nmosd yet approv predict similar
dynam new indic well
respect
compani focu rare ultrarar diseas well
unmatch efficaci soliri allow alexion
maintain substanti price power line rare-
ultra-rare-diseas drug soliri come high price
tag estim annual list net price soliri
pnh
ahu gmg meanwhil strensiq
kanuma price nontrivi net annual sum
per patient respect
per-pati cost extrem high overal burden
countri healthcar system small sinc number
affect patient extrem limit drug
clear disease-modifi benefit help justifi high price
facilit reimburs payer public
privat dynam allow alexion maintain
narrow band ex-u price
compani proactiv price ultomiri discount
soliri facilit patient convers new drug
list net price
indic strong patient convers crucial patient
share retent biosimilar competitor enter
pictur concern ultomiri price
discount absolut term drug still fetch
hefti figur even rare-diseas standard also first
year ultomiri includ seri initi load dose
actual put first year ultomiri roughli
premium soliri pnh dynam allow
compani captur valu crucial prebiosimilar
year patient convert maintain drug
cheaper long run
potenti brand competitor hurdl high bar
efficaci conveni establish soliri
ultomiri face signific barrier market entri
given alexion salesforc network patient
doctor mani alexion potenti brand competitor
inject self-administ alexion also
work subcutan form ultomiri
approv could enter market possibl sooner
believ alexion first-to-market statu soliri
strong efficaci ultomiri much conveni
dose schedul six seven infus per year versu
infus per year establish high barrier entri
even competitor succe reach regulatori
approv compet compani would face uphil
battl alexion global network patient
doctor well special salesforc
decad experi ultrarar rare diseas given
averag doctor never encount patient
one rare diseas career take
uniqu strategi identifi educ correct contact
soliri approv countri intang
asset gener alexion decade-plu global
experi rare autoimmun diseas easili
match competitor alexion recent launch
gmg testament compani experienc
commerci strategi compani nearli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
 patient roughli address patient
estim soliri less one year launch
despit fact gmg patient enrol
threat biosimilar loom label expans
believ alexion well-posit withstand
pressur competitor potenti entri earli
biosimilar like entri pnh
expand larger patient popul proactiv
price ultomiri discount offer conveni
dose soliri biosimilar would mean go back
doctor visit per year infus expect
reimburs issu ultomiri biosimilar
usual price discount origin drug
given ultomiri alreadi price discount
offer much conveni dose think like
alexion hold substanti share expect
pipelin ultomiri therapi includ intraven
form offer shorter infus time well weekli
biweekli monthli subcutan self-administ
inject form like bolster patient volum ward
signific ultomiri price headwind
pipelin competitor biosimilar entri pnh
like ahu gmg believ
patent-protect ultomiri label expans orphan
drug indic gmg approv nmosd
approv help compani retain moat intang
asset support moat weaken approach
end patent protect market exclus
look sever quantit qualit factor
consid moat trend return invest
capit econom profit steadili climb first
five year forecast recov larg
synageva acquisit howev soliri
patent expir signifi substanti weaken
alexion moat sourc intang asset compar
last sever year believ compani merit
neg moat trend wherea alexion narrow moat
cement clear patent protect think
forthcom like biosimilar hit price pressur
indic alexion competit posit
precari next five year compar past
believ strensiq kanuma alexion pipelin
off-set effect soliri biosimilar pipelin
prove promis new data would reconsid
moat trend note despit soliri patent expir
intang asset form compani substanti
experi identifi rare-diseas patient doctor
well mobil special salesforc remain
leverag salesforc patient identif
strategi strengthen econom moat like
way manag recent built pipelin sinc
compani restructur ad sever
candid rare indic high unmet need
anemia waiha light-chain amyloidosi
complement-medi indic reason acquisit
price pipelin candid wilson diseas
promis earli data compani initi
phase trial howev rest pipelin
earli stage yet confid
pipelin off-set alexion weaken intellectu
properti soliri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
osoliri ultomiri orphan drug statu
strong efficaci garner solid price power rare-
payer market share
oalexion abl leverag rare-diseas
expertis infrastructur effici identifi
patient doctor despit small address
olabel expans gener myasthenia gravi
neuromyel optica spectrum disord drive
oa subcutan competitor could reach market
alexion subcutan version take
soliri ultomiri compani key
ofailur quickli convert patient ultomiri
soliri would leav firm vulner competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
compani strong financi health healthi
balanc sheet portfolio drug provid good cash
gener compani issu billion debt
expens synageva acquisit
leisur pay alexion finish fiscal
billion long-term debt time
adjust ebitda estim compani earn
billion cash flow oper next three
year compani histori return cash
sharehold via stock repurchas expect
continu throughout explicit forecast model
unannounc acquisit possibl see
smaller deal next year manag
team see pipelin candid could good fit
compani
mount pressur competitor
biosimilar relianc soliri ultomiri
expect soliri ultomiri make
total revenu highlight compani potenti
concentr risk one key risk impact
competitor biosimilar although soliri closest
pipelin contend early-stag trial lucr
market size rare autoimmun space like
continu attract competit soliri patent
expir biosimilar could enter pnh market around
endang alexion hold indic
growth ultomiri rare indic offset
hit biosimilar forecast alexion face wide
rang possibl outcom long term launch
competitor molecul conveni method
dose could also captur materi portion soliri
market share alexion pois reach market
better version ultomiri less frequent intraven
dose competit well subcutan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
version regulatori failur could provid window
competitor launch subcutan version
alexion robust clinic program expand soliri
effort
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
fidel manag research compani
new york mellon corp
share
fund
share
fund
new manag record larg unprov
award alexion standard stewardship rate far
believ outlook promis given recent exampl
strong launch gmg approv ultomiri
pipelin acquisit
alexion histor stewardship turbul
result nearli complet leadership turnov throughout
much spur alleg aggress
sale practic subsequ investig
intern investig board audit financ
committe conclud histor financi statement
need restat howev compani soon
reduct addit chang
silver line improp sale probe
experienc execut baxalta merg
shire current alexion ceo ludwig
hantson led baxalta spin-off baxter
spent year novarti johnson johnson
also includ baxalta novarti addit
prior role neurov cfo paul clanci
previous serv cfo year aradhana
sarin chief strategi busi offic start
medic field work sever major
invest bank john orloff head research
develop year experi
biopharmaceut industri includ role baxalta
baxter merck novarti overal despit everyon
rel new tenur alexion bounti experi
give us confid manag team
well-posit lead compani forward
like way manag taken
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
initi build pipelin ad candid
wilson diseas warm autoimmun hemolyt anemia
light-chain amyloidosi complement-medi
indic reason acquisit price still
earli judg new manag acquisit record
acquir asset treat rare diseas high unmet
need line compani core focu strategi
sharp contrast prior manag decis
acquir synageva billion turn
bad bet difficult-to-diagnos metabol diseas
pipelin candid ultim fail clinic
develop kanuma come synageva
acquisit provid diversif increment
sale firm came steep price
alexion origin founder retir board
director director appoint
board also boast substanti
experi biopharmaceut industri nine
director independ like ceo
chairman role separ chairman david brennan
good fit given experi ceo astrazeneca
brennan led charg briefli compani
turbul period interim ceo
help secur solid current manag team
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
alexion convers ultomiri ahead schedul
oper result total revenu billion
last year soliri approv four rare
diseas contribut million revenu
last year soliri double-digit volum growth off-set
price headwind canada may small
impact rest year metabol drug strensiq
kanuma post double-digit growth
contribut million follow quarter strong
result manag rais guidanc full year
may make adjust model
anticip materi chang fair valu estim
pleas see ultomiri surpass
expect million revenu second
quarter doubl revenu first quarter
manag report paroxysm nocturn
hemoglobinuria pnh patient switch
soliri approach patent expir ultomiri
offer conveni dose schedul everi
two month slightli lower price mean alexion
track well goal convert pnh patient
ultomiri end success patient
convers soliri ultomiri remain key pillar
narrow moat rate believ alexion
abl avoid sever sale declin despit inevit
biosimilar entri patient hesit switch
back soliri inconveni dose schedul everi two
compani sever advanc clinic trial initi
includ phase superior trial
wilson diseas phase trial
warm autoimmun hemolyt anemia
phase trial al amyloidosi
expect research develop cost grow
doubl digit year remain total
revenu medium term
compani announc addit already-
abund pipelin clinic trial plan initi
phase trial ultomiri hematopoiet stem cell
thrombot microangiopathi
hsct-tma seriou complic stem cell transplant
approv treatment option may
off-label use alexion therapi indic
alexion share earli trial result
yet includ model competitor
narsoplimab nomacopan coversin
alreadi trial way hsct-tma alexion
experi clinic develop compar
small competitor suggest compani could catch
quickli expand address patient
popul ultomiri
give littl credit rest alexion pipelin
model point given mani candid still
earli stage includ plan trial
gener myasthenia gravi ultomiri primari
progress multipl sclerosi amyotroph later
sclerosi overal compani focu rare
diseas high unmet need strong price power
see path continu excess return support
fda approv alexion blockbust drug soliri
 food drug administr soliri
subset patient diagnos neuromyel optica
spectrum disord rare chronic disord brain
spinal cord approv treatment nmosd
fit well alexion strategi target rare indic
high unmet need maintain fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
estim per share given posit late-stag
clinic result publish earlier year believ
share look attract
approv provid treatment
posit patient make least two third
total patient popul compani estim
elig patient unit state
significantli expand address popul
soliri current approv ultrarar paroxysm
urem syndrom rare gener myasthenia gravi
given larger popul size estim nmosd
could contribut largest portion revenu
ultrarar price tag sizabl address patient
popul soliri uniqu success stori drawn
competitor space complement-medi
disord includ apelli pharmaceut
finish enrol late-stag trial pnh compar
soliri howev continu believ
expir pnh ahu market exclus gmg
nmosd continu drive excess return
opinion valuat narrow moat rate
depend success launch ultomiri alexion next-
gener therapi conveni dose schedul
ultomiri alreadi approv pnh expect
decis fda ahu octob
see one key risk soliri launch nmosd
diseas difficult diagnos
character recur attack mistaken
disord multipl sclerosi name
suggest nmosd present spectrum mild
sever symptom includ attack weak paralysi
blind howev believ soliri strong launch
gmg testament compani educ
market strategi valuat depend strong
launch intern approv
estim nmosd sale soliri could reach billion
next year
alexion beat expect full steam ahead
ultomiri convers neurolog push apr
alexion report solid quarter revenu adjust
earn per share ahead expect
manag rais guidanc slightli effort convert
patient soliri
approach patent
expir ultomiri approv
januari well underway soliri launch
gener myasthenia gravi gmg continu drive
growth may adjust near-term estim
slightli expect materi chang fair valu
estim per share continu believ
market underappreci intang asset
behind alexion portfolio rare diseas narrow
first-quart revenu billion repres
growth last year driven soliri newli launch
ultomiri complement-medi diseas strensiq
kanuma rare metabol disord perform line
expect soliri driven
volum growth slightli off-set expect price
currenc headwind full year model high-single-
digit volum growth paroxysm nocturn hemoglobinuria
pnh atyp hemolyt urem syndrom ahu
strong uptak gmg compani report
gmg patient soliri mid-april slightli ahead
expect strong top-lin growth help boost
adjust oper margin basi point
oper expens project
first quarter anticip much chang
full-year outlook given sever trial pick
back half slightli later
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
europ call manag state russian
biosimilar approv anticip alreadi
incorpor previou guidanc manag
surmis biosimilar current phase
trial would take three year enter market
line model
main catalyst year alexion progress
soliri nmosd would strengthen posit
neurolog expect detail phase data soliri
nmosd may follow posit top-lin result last
septemb well potenti approv late june
like see strong launch nmosd later year
approv would indic compani
progress shift ultra-rar indic rare
indic larger target popul strong price
power given nmosd character
relaps altern off-label treatment
strong launch would testament compani
commerci strategi potenti challeng
mani trial ultomiri
approv pnh expect garner sever approv
come year alexion continu strategi
convert patient soliri ultomiri manag
report compani file approv ultomiri
ahu put track launch
approv also model launch gmg
late-stag trial alreadi underway neuromyel
optica spectrum disord nmosd late-stag trial
plan late compani also recent
amyotroph later sclerosi al primari progress
multipl sclerosi ppm opportun earli
model especi given challeng neurolog
disord
ultomiri contribut million revenu first
quarter slightli expect still healthi
indic convers effort compani cite
pnh patient alreadi ultomiri treatment
sizabl progress toward compani goal
convers end expect convers
momentum slow throughout year effort
move earli adopt approv
subcutan dose instead intraven would
import boon compani hit efficaci
conveni late-stag trial subcutan ultomiri
underway pnh ahu expect
launch leav room potenti brand
earlier month first biosimilar soliri
approv russia anticip signific
impact outsid russia commonwealth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
